Tags

Type your tag names separated by a space and hit enter

MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis.
Int J Mol Sci. 2020 Jun 24; 21(12)IJ

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease caused by the loss of motor neurons. Although the pathogenesis of sporadic ALS (sALS) remains unclear, it has recently been suggested that disorders of microRNA (miRNA) may be involved in neurodegenerative conditions. The purpose of this study was to investigate miRNA levels in sALS and the target genes of miRNA. Microarray and real-time RT-PCR analyses revealed significantly-decreased levels of miR-139-5p and significantly increased levels of miR-5572 in the spinal cords of sALS patients compared with those in controls. We then focused on miR-5572, which has not been reported in ALS, and determined its target gene. By using TargetScan, we predicted SLC30A3 as the candidate target gene of miR-5572. In a previous study, we found decreased SLC30A3 levels in the spinal cords of sALS patients. We revealed that SLC30A3 was regulated by miR-5572. Taken together, these results demonstrate that the level of novel miRNA miR-5572 is increased in sALS and that SLC30A3 is one of the target genes regulated by miR-5572.

Links

Authors+Show Affiliations

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

Department of Pathology, Brain Research Institute, Niigata University, 1 Asahimachi, Chuo-ku, Niigata 951-8585, Japan.

Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.

MeSH

Amyotrophic Lateral SclerosisBiomarkersCase-Control StudiesCation Transport ProteinsGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32599739

Citation

Kurita, Hisaka, et al. "MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis." International Journal of Molecular Sciences, vol. 21, no. 12, 2020.

Kurita H, Yabe S, Ueda T, et al. MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020;21(12).

Kurita, H., Yabe, S., Ueda, T., Inden, M., Kakita, A., & Hozumi, I. (2020). MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 21(12). https://doi.org/10.3390/ijms21124482

Kurita H, et al. MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020 Jun 24;21(12) PubMed PMID: 32599739.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis. AU - Kurita,Hisaka, AU - Yabe,Saori, AU - Ueda,Tomoyuki, AU - Inden,Masatoshi, AU - Kakita,Akiyoshi, AU - Hozumi,Isao, Y1 - 2020/06/24/ PY - 2020/05/28/received PY - 2020/06/19/revised PY - 2020/06/22/accepted PY - 2020/7/1/entrez PY - 2020/7/1/pubmed PY - 2021/3/23/medline KW - amyotrophic lateral sclerosis KW - microRNA KW - microarray KW - spinal cord JF - International journal of molecular sciences JO - Int J Mol Sci VL - 21 IS - 12 N2 - Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease caused by the loss of motor neurons. Although the pathogenesis of sporadic ALS (sALS) remains unclear, it has recently been suggested that disorders of microRNA (miRNA) may be involved in neurodegenerative conditions. The purpose of this study was to investigate miRNA levels in sALS and the target genes of miRNA. Microarray and real-time RT-PCR analyses revealed significantly-decreased levels of miR-139-5p and significantly increased levels of miR-5572 in the spinal cords of sALS patients compared with those in controls. We then focused on miR-5572, which has not been reported in ALS, and determined its target gene. By using TargetScan, we predicted SLC30A3 as the candidate target gene of miR-5572. In a previous study, we found decreased SLC30A3 levels in the spinal cords of sALS patients. We revealed that SLC30A3 was regulated by miR-5572. Taken together, these results demonstrate that the level of novel miRNA miR-5572 is increased in sALS and that SLC30A3 is one of the target genes regulated by miR-5572. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/32599739/MicroRNA_5572_Is_a_Novel_MicroRNA_Regulating_SLC30A3_in_Sporadic_Amyotrophic_Lateral_Sclerosis_ DB - PRIME DP - Unbound Medicine ER -